Components of the pathway, including growth factor receptors, regulators of RAS, the RAS proteins themselves, BRAF, MEK1 and MEK2 are mutated in a variety of cancers, resulting in hyperactivation of ERK1/2 signalling which underpins the growth and maintenance of many tumour types. This evidence concerns the gene BRAF and cancer.